EMERYVILLE, Calif., Oct. 22, 2020 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, will report third quarter 2020 financial results on Thursday, November 5, 2020, after the U.S. financial markets close.
Dynavax will host a conference call and live audio webcast on Thursday, November 5, 2020 at 4:30 p.m. (ET)/1:30 p.m. (PT).
The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at www.dynavax.com. Alternatively, participants may dial (866) 420-4066 (domestic) or (409) 217-8237 (international) and refer to conference ID 1475431. A replay of the webcast will be available for 30 days following the live event.
About Dynavax
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza. For more information, visit www.dynavax.com and follow the company on LinkedIn.
Contacts:
Nicole Arndt, Senior Manager, Investor Relations
narndt@dynavax.com
510-665-7264
Derek Cole, President
Investor Relations Advisory Solutions
derek.cole@IRadvisory.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/dynavax-to-report-third-quarter-2020-financial-results-and-host-conference-call-on-november-5-2020-301158328.html
SOURCE Dynavax Technologies
